ClinicalTrials.gg
Active, not recruitingNCT07496450Updated Aug 11, 2026

A Study of mRNA-1018-H5 Pandemic Influenza Vaccine in Healthy Adults

A Phase 3 interventional study of mRNA-1018-H5 and Placebo in Influenza, sponsored by ModernaTX, Inc.. Active, not recruiting at 35 sites in 2 countries. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-08-11.

Sponsored by ModernaTX, Inc. (part of Moderna, Inc.) · Phase 3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
4,050
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 23 studies in Influenza, Human by Moderna, Inc. — 2 open to participants now, 3 under way, 1 of them phase 3. Influenza, Human · Moderna, Inc..

Enrollment
6th of 23
4,050 · median 885
Started
2026
with 2 others
Phase 3
7 of 23
none open now
Registered
21st of 23
by date

Among the 23 studies in Influenza, Human by Moderna, Inc., this one is the 6th largest by enrollment, is one of 3 that started in 2026, is one of 7 in phase 3, and was the 21st registered.

Influenza, Human

2,361 studies on the registry are indexed under Influenza, Human; 186 are open to participants now.

Browse Influenza, Human studies →

Open to participants now

2 of the 23 studies in Influenza, Human by Moderna, Inc. are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 124 Influenza, Human studies recruiting now, 67 (54%) set no upper age limit and 47 (38%) stop at 75 or younger; 34 take children under 18; 69 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies in Influenza, Human by Moderna, Inc., or all of them as a file.
02

Study summary

The purpose of this study is to evaluate humoral immunogenicity after 2 doses of mRNA-1018-H5, and to evaluate the safety and reactogenicity of mRNA-1018-H5 in adults ≥18 years of age.

03

Conditions studied

  • Influenza

Keywords

  • Influenza Vaccine
  • Moderna
  • mRNA-1018-H5
  • Viral Diseases
  • Vaccines
  • Pandemic Influenza
  • Avian Flu
  • Bird Flu
  • Influenza A
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Key Inclusion Criteria:

  • Healthy as determined by medical evaluation including medical history; and physical examination. Participants with clinically stable chronic medical conditions are permitted.
  • Participants who are assigned female at birth or could become pregnant are eligible to participate if the participant is not pregnant or breast/chest feeding, and one of the following conditions applies:

    • Is a person of nonchildbearing potential (PONCBP) OR
    • Is a person of (POCBP)
    • A POCBP must have a negative highly sensitive pregnancy test at Screening and on the day of the first dose of study intervention.

Key Exclusion Criteria:

  • Participant is acutely ill or febrile (body temperature ≥ 38.0 degrees Celsius [°C]/100.4 degrees Fahrenheit [°F]) within 72 hours prior to or at the Screening Visit or Day 1.
  • History of myocarditis, pericarditis, or myopericarditis.
  • History of Guillain-Barre syndrome.
  • Reported history of congenital or acquired immunodeficiency, condition, asplenia, or recurrent severe infections disease.
  • Treated with antiviral therapies for influenza (eg, Tamiflu, Xofluza) within 28 days prior to Day 1.
  • Prior receipt of a pandemic influenza vaccine or participation in any pandemic influenza vaccine clinical study, including the mRNA-1018-P101 study.
  • Any medical, psychiatric, or occupational condition, that, in the opinion of the Investigator, might pose additional risk due to participation in the study or could interfere with adherence to study procedures or the interpretation of study results.
  • Participant has received systemic immunosuppressants including long-acting biological therapies that affect immune responses (eg, infliximab, methotrexate, omalizumab, etc.), within 180 days prior to Screening or plans to do so at any time during participation in the study.
  • Participant has received at ≥10 mg/day of prednisone or equivalent for >14 days in total within 90 days prior to Day 1 (Baseline) or is anticipating the need for corticosteroids at any time during the study.
  • Participants has received any licensed vaccine authorized or approved by local health agency including mRNA vaccine ≤28 days prior to study intervention (Day 1) or plans to receive a vaccine authorized or approved by local health agency within 21 days after the study intervention.
  • Participant has participated in an interventional clinical study within 90 days prior to the Screening visit based on the medical history interview or plans to do so while participating in this study.

Note: Other inclusion/exclusion criteria may apply.

Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
4,050 participants (actual)

Study arms

  • Experimental
    mRNA-1018-H5 Vaccine

    Participants will receive mRNA-1018-H5 vaccine by intramuscular (IM) injection on Day 1 and Day 22.

    Biological: mRNA-1018-H5

  • Placebo comparator
    Placebo

    Participants will receive placebo matched to mRNA-1018-H5 vaccine by IM injection on Day 1 and Day 22.

    Biological: Placebo

Interventions

  • BiologicalmRNA-1018-H5

    Sterile liquid for injection.

  • BiologicalPlacebo

    Sterile liquid for injection.

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Hemagglutination Inhibition (HAI) Titer ≥ 1:40 at Day 43

    HAI Titer \>=1:40.

    Time frame: Day 43

  2. Percentage of Participants With Seroconversion at Day 43, as Measured by HAI Assay

    Seroconversion is defined as a Day 43 titer ≥1:40 if baseline is \<1:10 or a 4-fold or greater rise if baseline is ≥1:10 in HAI titer measured by HAI assay.

    Time frame: Day 43

  3. Number of Participants with Solicited Local and Systemic Adverse Reactions (ARs)

    Time frame: Up to Day 29 (7 days after each injection)

  4. Number of Participants with Unsolicited Adverse Events (AEs)

    Time frame: Up to Day 50 (28 days after each injection)

  5. Number of Participants with AEs Leading to Discontinuation, Medically-attended AEs (MAAEs), Serious Adverse Events (SAEs), Adverse Events of Special Interest (AESIs)

    Time frame: Day 1 to Day 205

Secondary outcomes

  1. Geometric Mean Titer (GMT) of Anti-H5N1 Antibodies at Day 43, as Measured by Microneutralization (MN) Assay

    Time frame: Day 43

  2. GMT of HAI Antibodies at Days 22 and 205, as Measured by HAI Assay

    Time frame: Days 22 and 205

  3. GMT of HAI Antibodies at Days 22 and 205, as Measured by MN Assay

    Time frame: Days 22 and 205

  4. Percentage of Participants with HAI Titers at Different Cut-Offs

    Cutoff included \>= 1:80.

    Time frame: Up to Day 205

07

Study locations

35 sites
  • Velocity Clinical Research, San Bernardino
    San Bernardino, California 92408, United States
  • Velocity Clinical Research, Savannah
    Savannah, Georgia 31406, United States
  • Velocity Clinical Research, Boise
    Meridian, Idaho 83642, United States
  • Velocity Clinical Research, Rockville
    Rockville, Maryland 20854, United States
  • Velocity Clinical Research, Omaha
    Omaha, Nebraska 68134, United States
  • Velocity Clinical Research, Cleveland
    Beachwood, Ohio 44122, United States
  • Velocity Clinical Research, Providence
    East Greenwich, Rhode Island 02818, United States
  • Velocity Clinical Research, Anderson
    Anderson, South Carolina 29621, United States
  • Velocity Clinical Research, Dallas
    Dallas, Texas 75230, United States
  • Velocity Clinical Research, Suffolk
    Suffolk, Virginia 23435, United States
  • Velocity Clinical Research-Bristol
    Bristol, Bristol (Unitary Authority) BS8 2RA, United Kingdom
  • Velocity Clinical Research - High Wycombe
    High Wycombe, Buckinghamshire HP11 2QW, United Kingdom
  • Wansford Research Ltd
    Peterborough, Cambridgeshire PE8 6PL, United Kingdom
  • Futuremeds Teesside Middlefield Centre University Hospital of North Tees
    Stockton-on-Tees, County Durham TS19 8PE, United Kingdom
  • NIHR Wessex CRDC - Bournemouth Research Hub (Under University Hospital Southampton NHS Foundation Trust)
    Bournemouth, Dorset BH7 7DW, United Kingdom
  • NIHR Wessex CRDC - Weymouth Research Hub (Under University Hospital Southampton NHS Foundation Trust)
    Weymouth, Dorset DT4 0QE, United Kingdom
  • Panthera Glasgow
    Glasgow, Glasgow City (Scotland) G51 4TF, United Kingdom
  • Panthera Enfield
    Enfield, Greater London EN3 4GS, United Kingdom
  • Hounslow Medical Centre
    Hounslow, Greater London TW3 3ET, United Kingdom
  • hVIVO Services Limited
    London, Greater London E1 1EQ, United Kingdom
  • Velocity Clinical Research-North London
    London, Greater London N12 8BU, United Kingdom
  • Accellacare North London
    Northwood, Greater London HA6 2RN, United Kingdom
  • Accellacare South London
    Orpington, Greater London BR5 3QG, United Kingdom
  • Velocity Clinical Research-Romford
    Romford, Greater London RM1 3PJ, United Kingdom
  • Panthera Rochdale
    Rochdale, Greater Manchester OL11 4AU, United Kingdom
  • NIHR Wessex CRDC - Southampton Research Hub (Under University Hospital Southampton NHS FT)
    Southampton, Hampshire SO15 3UA, United Kingdom
  • Fylde Coast Clinical Research at Layton Medical Centre
    Blackpool, Lancashire FY3 7EN, United Kingdom
  • FutureMeds Liverpool
    Metropolitan Borough of Wirral, Merseyside CH62 6EE, United Kingdom
  • Lakeside Healthcare
    Corby, North Northamptonshire NN17 2UR, United Kingdom
  • Panthera York
    York, North Yorkshire YO24 4LJ, United Kingdom
  • The University of Nottingham Health Service
    Nottingham, Nottinghamshire NG7 2QW, United Kingdom
  • Panthera Sheffield
    Sheffield, South Yorkshire S2 5FX, United Kingdom
  • Accellacare Warwickshire
    Coventry, West Midlands (Coventry) CV3 4FJ, United Kingdom
  • FutureMeds Birmingham Soho Road Health Centre
    Birmingham, West Midlands B21 9RY, United Kingdom
  • Accellacare Yorkshire
    Shipley, West Yorkshire BD18 3SA, United Kingdom
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2026 (actual). Primary completion is estimated for Jan 2027, 10 months after the start.

Of 119 industry-sponsored phase 3 interventional studies under Influenza, Human, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 14. This study's planned 10 months is above that.

Counting every sponsor, half of 154 studies reached it within 8 months; a quarter within 4 and three quarters within 15.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 22, 2026
First posted
Mar 27, 2026
StartActual
Mar 23, 2026
Primary completionEst.
Jan 28, 2027
CompletionEst.
Jan 28, 2027
Last update
Aug 11, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 11, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07496450
Lead sponsor
ModernaTX, Inc.
Responsible party
Sponsor
First posted
Mar 27, 2026
Start date
Mar 23, 2026
Primary completion
Jan 28, 2027 (estimated)
Completion
Jan 28, 2027 (estimated)
Last update
Aug 11, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion